CL2013000714A1 - Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras. - Google Patents
Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras.Info
- Publication number
- CL2013000714A1 CL2013000714A1 CL2013000714A CL2013000714A CL2013000714A1 CL 2013000714 A1 CL2013000714 A1 CL 2013000714A1 CL 2013000714 A CL2013000714 A CL 2013000714A CL 2013000714 A CL2013000714 A CL 2013000714A CL 2013000714 A1 CL2013000714 A1 CL 2013000714A1
- Authority
- CL
- Chile
- Prior art keywords
- gpr119
- dyslipidemia
- schizophrenia
- modulators
- hypertension
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 2
- 208000032928 Dyslipidaemia Diseases 0.000 title 1
- 206010020772 Hypertension Diseases 0.000 title 1
- 208000017170 Lipid metabolism disease Diseases 0.000 title 1
- 208000001145 Metabolic Syndrome Diseases 0.000 title 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 150000003951 lactams Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000003386 piperidinyl group Chemical group 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38379910P | 2010-09-17 | 2010-09-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013000714A1 true CL2013000714A1 (es) | 2013-10-11 |
Family
ID=44736053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013000714A CL2013000714A1 (es) | 2010-09-17 | 2013-03-15 | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20130184257A1 (es) |
| EP (1) | EP2616074A1 (es) |
| JP (1) | JP2013537234A (es) |
| KR (1) | KR20130099970A (es) |
| CN (1) | CN103221046A (es) |
| AR (1) | AR083003A1 (es) |
| AU (1) | AU2011301934A1 (es) |
| BR (1) | BR112013006344A2 (es) |
| CA (1) | CA2811525A1 (es) |
| CL (1) | CL2013000714A1 (es) |
| CR (1) | CR20130173A (es) |
| IL (1) | IL225214A0 (es) |
| MX (1) | MX2013003034A (es) |
| PH (1) | PH12013500472A1 (es) |
| RU (1) | RU2013117403A (es) |
| SG (1) | SG188985A1 (es) |
| TW (1) | TW201213322A (es) |
| UY (1) | UY33614A (es) |
| WO (1) | WO2012037393A1 (es) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2012154308A (ru) | 2010-05-17 | 2014-06-27 | Эррэй Биофарма Инк. | Пиперидинил-замещенные лактамы как модуляторы gpr119 |
| WO2012170867A1 (en) | 2011-06-09 | 2012-12-13 | Rhizen Pharmaceuticals Sa | Novel compounds as modulators of gpr-119 |
| JP6083818B2 (ja) | 2011-11-18 | 2017-02-22 | ヘプタレス セラピューティクス リミテッドHeptares Therapeutics Limited | ムスカリンm1受容体アゴニスト |
| CA2878625A1 (en) | 2012-07-11 | 2014-01-16 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
| AR092924A1 (es) | 2012-10-09 | 2015-05-06 | Sanofi Sa | Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
| GB201404922D0 (en) | 2014-03-19 | 2014-04-30 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| TW201625605A (zh) | 2014-04-04 | 2016-07-16 | 賽諾菲公司 | 用於治療糖尿病、肥胖、血脂異常及相關病症之作為gpr119調節劑的經取代之稠合雜環類 |
| AR099937A1 (es) | 2014-04-04 | 2016-08-31 | Sanofi Sa | Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados |
| CA2942121A1 (en) | 2014-04-04 | 2015-10-08 | Sanofi | Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
| CN104672116B (zh) * | 2015-02-13 | 2016-06-01 | 佛山市赛维斯医药科技有限公司 | 一种含苯磺酰肼和腈基苯结构gpr119激动剂及其用途 |
| CN104892517A (zh) * | 2015-02-13 | 2015-09-09 | 佛山市赛维斯医药科技有限公司 | 酰肼类化合物、其制备方法及用途 |
| CN104610151A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 含酰肼和烷氧苯类结构的化合物、其制备方法及用途 |
| UY36586A (es) | 2015-03-26 | 2016-10-31 | Bayer Pharma AG | Heterociclilmetiltienouracilos y uso de los mismos |
| GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
| GB201519352D0 (en) | 2015-11-02 | 2015-12-16 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
| WO2018153849A1 (en) | 2017-02-21 | 2018-08-30 | Sanofi | Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders |
| GB201810245D0 (en) * | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB201819961D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
| PH12022552277A1 (en) | 2020-02-28 | 2024-03-04 | Kallyope Inc | Gpr40 agonists |
| JP2023526625A (ja) | 2020-05-19 | 2023-06-22 | キャリーオペ,インク. | Ampkアクチベーター |
| CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| CA2661371A1 (en) * | 2006-08-30 | 2008-03-06 | Biovitrum Ab (Publ) | Pyrimidine compounds for treating gpr119 related disorders |
| ES2387865T3 (es) * | 2008-07-10 | 2012-10-03 | Prosidion Ltd | Agonistas de GPCR de piperidina |
-
2011
- 2011-09-15 KR KR1020137009752A patent/KR20130099970A/ko not_active Withdrawn
- 2011-09-15 CN CN2011800554986A patent/CN103221046A/zh active Pending
- 2011-09-15 RU RU2013117403/04A patent/RU2013117403A/ru not_active Application Discontinuation
- 2011-09-15 US US13/823,041 patent/US20130184257A1/en not_active Abandoned
- 2011-09-15 MX MX2013003034A patent/MX2013003034A/es not_active Application Discontinuation
- 2011-09-15 AU AU2011301934A patent/AU2011301934A1/en not_active Abandoned
- 2011-09-15 WO PCT/US2011/051821 patent/WO2012037393A1/en not_active Ceased
- 2011-09-15 JP JP2013529341A patent/JP2013537234A/ja not_active Withdrawn
- 2011-09-15 BR BR112013006344A patent/BR112013006344A2/pt not_active Application Discontinuation
- 2011-09-15 PH PH1/2013/500472A patent/PH12013500472A1/en unknown
- 2011-09-15 CA CA2811525A patent/CA2811525A1/en not_active Abandoned
- 2011-09-15 EP EP11764392.4A patent/EP2616074A1/en not_active Withdrawn
- 2011-09-15 SG SG2013018551A patent/SG188985A1/en unknown
- 2011-09-16 AR ARP110103373A patent/AR083003A1/es not_active Application Discontinuation
- 2011-09-16 TW TW100133495A patent/TW201213322A/zh unknown
- 2011-09-16 UY UY0001033614A patent/UY33614A/es not_active Application Discontinuation
-
2013
- 2013-03-14 IL IL225214A patent/IL225214A0/en unknown
- 2013-03-15 CL CL2013000714A patent/CL2013000714A1/es unknown
- 2013-04-17 CR CR20130173A patent/CR20130173A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201213322A (en) | 2012-04-01 |
| CN103221046A (zh) | 2013-07-24 |
| AU2011301934A1 (en) | 2013-05-16 |
| CR20130173A (es) | 2013-05-15 |
| IL225214A0 (en) | 2013-06-27 |
| JP2013537234A (ja) | 2013-09-30 |
| MX2013003034A (es) | 2013-08-15 |
| SG188985A1 (en) | 2013-05-31 |
| US20130184257A1 (en) | 2013-07-18 |
| UY33614A (es) | 2013-04-05 |
| PH12013500472A1 (en) | 2013-04-29 |
| BR112013006344A2 (pt) | 2016-06-21 |
| WO2012037393A1 (en) | 2012-03-22 |
| RU2013117403A (ru) | 2014-10-27 |
| CA2811525A1 (en) | 2012-03-22 |
| KR20130099970A (ko) | 2013-09-06 |
| EP2616074A1 (en) | 2013-07-24 |
| AR083003A1 (es) | 2013-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013000714A1 (es) | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras. | |
| CL2012003211A1 (es) | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas | |
| EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201270720A1 (ru) | Модуляторы рецептора андрогенов и их применение | |
| EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201691070A1 (ru) | Новые трициклические соединения в качестве противораковых средств | |
| CO6480918A2 (es) | Antagonistas policíclicos de receptores de ácido lisofosfatídico. | |
| CL2014000956A1 (es) | Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor. | |
| MX2016014308A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| EA201200570A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| CO6751270A2 (es) | Compuestos y composiciones como inhibidores de la trk | |
| EA201690044A1 (ru) | Модуляторы ядерного транспорта и их применение | |
| EA201492050A1 (ru) | Модуляторы ядерного транспорта и их применение | |
| EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201391561A1 (ru) | Новые соединения-модуляторы gpr-119 | |
| CL2011003147A1 (es) | Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer. | |
| HK1213264A1 (zh) | 经取代的苯化合物 | |
| UY33597A (es) | Compuestos y composiciones como inhibidores de la trk | |
| CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
| ECSP12011720A (es) | Compuestos heterocíclicos y usos de los mismos | |
| EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
| EA201492216A1 (ru) | Ингибиторы бромодомена и их применение | |
| BR112014007163A2 (pt) | composições farmacêuticas de n-metil-2 [3 ((e)-2 piridin-2 il-vinil)-1h-indazol-6 ilsulfanil]-benzamida | |
| CL2015000956A1 (es) | Compuestos derivados de pirrolotriazinona como inhibidores de pi3k; composicion farmaceutica que los comprende; combinacion farmaceutica; uso para tratar enfermedades respiratorias, autoinmunes, trastornos neurologicos, cardiovasculares, metabolicos, entre otros. |